Merck Consumer Health Care

merck-china.com

Merck is a global pharmaceutical and chemical company with a history that began in 1668, and a future shaped by around 40,000 employees in 64 countries. With the acquisition of Millipore in July 2010, a global leader in the life science tools market, pro forma revenues totaled around EUR 8.9 billion in 2009. Innovations made possible by entrepreneurial employees characterize the company’s success. Merck's operating activities are combined under the umbrella of Merck KGaA, in which the Merck family indirectly holds an interest of approximately 70%. The remaining 30% is publicly traded.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

ACTIVE PHARMA INGREDIENT MARKET TO SEE ONGOING EVOLUTION 2027

openPR | April 09, 2020

news image

Stratagem Market Insights has announced the addition of the "Active Pharma Ingredient Market Report 2020-2027 Production, Sales And Consumption Status And Prospects Professional Research", The report classifies the global Active Pharma Ingredient Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth. Active Pharmaceutical Ingredient (API) produces the intended effects in a drug. A drug can contain a singl...

Read More

Pharmacy Market

NOW AVAILABLE – XDEMVY™ (LOTILANER OPHTHALMIC SOLUTION) 0.25%, THE FIRST AND ONLY FDA APPROVED TREATMENT FOR DEMODEX BLEPHARITIS

globenewswire | August 28, 2023

news image

Tarsus Pharmaceuticals, Inc. whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, announced that XDEMVY™ (lotilaner ophthalmic solution) 0.25% is now available at pharmacies nationwide for prescription. The U.S. Food and Drug Administration (FDA) approved XDEMVY on July 24, 2023, for the treatment of Demodex blepharitis. “We are delighted that within weeks of FDA approval...

Read More

Business Insights, PHARMACY MARKET

COEUS HOLDINGS ANNOUNCES REBRANDING TO REFLECT THE UNIFICATION OF EACH BUSINESS UNIT INTO ONE ENTITY

Businesswire | May 02, 2023

news image

COEUS, a leading healthcare communications, technology, talent, and consulting firm delivering a variety of services and platforms to all stakeholders in the healthcare ecosystem, announced today that it has completed a major rebranding. Following nearly 14 years of both organic growth and acquisitions, all business units have been combined to form one entity: COEUS. Since the company’s inception in 2009, the company sought to build a suite of services capable of providing...

Read More

Pharma Tech

FEDS REBUFF PFIZER'S PLEAS TO SPEED UP SUPPLIES OF COVID-19 VACCINE RAW MATERIALS

Pfizer | December 21, 2020

news image

Since the time Pfizer was fixed to partake in the U.S. government's Warp Speed exertion to get COVID-19 antibodies to showcase, the organization has made it very clear it didn't have to take any bureaucratic cash to build up the immunization. In any case, did that refusal of R&D subsidizing add to Pfizer's failure to produce more dosages of its mRNA antibody for the U.S. market? Pfizer could give more than the 100 million portions it guaranteed in it...

Read More
news image

ACTIVE PHARMA INGREDIENT MARKET TO SEE ONGOING EVOLUTION 2027

openPR | April 09, 2020

Stratagem Market Insights has announced the addition of the "Active Pharma Ingredient Market Report 2020-2027 Production, Sales And Consumption Status And Prospects Professional Research", The report classifies the global Active Pharma Ingredient Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth. Active Pharmaceutical Ingredient (API) produces the intended effects in a drug. A drug can contain a singl...

Read More
news image

Pharmacy Market

NOW AVAILABLE – XDEMVY™ (LOTILANER OPHTHALMIC SOLUTION) 0.25%, THE FIRST AND ONLY FDA APPROVED TREATMENT FOR DEMODEX BLEPHARITIS

globenewswire | August 28, 2023

Tarsus Pharmaceuticals, Inc. whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, announced that XDEMVY™ (lotilaner ophthalmic solution) 0.25% is now available at pharmacies nationwide for prescription. The U.S. Food and Drug Administration (FDA) approved XDEMVY on July 24, 2023, for the treatment of Demodex blepharitis. “We are delighted that within weeks of FDA approval...

Read More
news image

Business Insights, PHARMACY MARKET

COEUS HOLDINGS ANNOUNCES REBRANDING TO REFLECT THE UNIFICATION OF EACH BUSINESS UNIT INTO ONE ENTITY

Businesswire | May 02, 2023

COEUS, a leading healthcare communications, technology, talent, and consulting firm delivering a variety of services and platforms to all stakeholders in the healthcare ecosystem, announced today that it has completed a major rebranding. Following nearly 14 years of both organic growth and acquisitions, all business units have been combined to form one entity: COEUS. Since the company’s inception in 2009, the company sought to build a suite of services capable of providing...

Read More
news image

Pharma Tech

FEDS REBUFF PFIZER'S PLEAS TO SPEED UP SUPPLIES OF COVID-19 VACCINE RAW MATERIALS

Pfizer | December 21, 2020

Since the time Pfizer was fixed to partake in the U.S. government's Warp Speed exertion to get COVID-19 antibodies to showcase, the organization has made it very clear it didn't have to take any bureaucratic cash to build up the immunization. In any case, did that refusal of R&D subsidizing add to Pfizer's failure to produce more dosages of its mRNA antibody for the U.S. market? Pfizer could give more than the 100 million portions it guaranteed in it...

Read More